Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Nelonemdaz

From Wikipedia, the free encyclopedia
(Redirected fromSafaprodil)
Chemical compound
Pharmaceutical compound
Nelonemdaz
Legal status
Legal status
  • Investigational
Identifiers
  • 2-Hydroxy-5-[[2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl]methylamino]benzoic acid
CAS Number
PubChemCID
UNII
Chemical and physical data
FormulaC15H8F7NO3
Molar mass383.222 g·mol−1
3D model (JSmol)
  • C1=CC(=C(C=C1NCC2=C(C(=C(C(=C2F)F)C(F)(F)F)F)F)C(=O)O)O
  • InChI=1S/C15H8F7NO3/c16-10-7(11(17)13(19)9(12(10)18)15(20,21)22)4-23-5-1-2-8(24)6(3-5)14(25)26/h1-3,23-24H,4H2,(H,25,26)
  • Key:HABROHXUHNHQMY-UHFFFAOYSA-N

Nelonemdaz is an experimental drug that works as afree radical reducer and selective antagonist of theNMDA receptor 2b. It is hypothesized to have neuroprotective effects in people who recently experienced astroke.[1][2][3][4]

References

[edit]
  1. ^Xu, Xiumei; Chen, Mingyu; Zhu, Dongya (13 October 2023)."Reperfusion and cytoprotective agents are a mutually beneficial pair in ischaemic stroke therapy: an overview of pathophysiology, pharmacological targets and candidate drugs focusing on excitotoxicity and free radical".Stroke and Vascular Neurology.9 (4): svn–2023–002671.doi:10.1136/svn-2023-002671.PMC 11420919.PMID 37832977.
  2. ^Lee, Jin Soo; Lee, Ji Sung; Gwag, Byoung Joo; Choi, Dennis W; An, Chun San; Kang, Hyun Goo; Song, Tae-Jin; Ahn, Seong Hwan; Kim, Chang Hun; Kwon, Sun U (February 2023). "Abstract TP15: Rationale And Ongoing Status In A Phase 3 Trial Of Nelonemdaz, A Novel Neuroprotection Drug, For Patients With Acute Ischemic Stroke And Reperfusion".Stroke.54 (Suppl_1).doi:10.1161/str.54.suppl_1.TP15.S2CID 256564237.
  3. ^Lee, Jin Soo; Lee, Ji Sung; Gwag, Byoung Joo; Choi, Dennis W.; An, Chun San; Kang, Hyun Goo; Song, Tae-Jin; Ahn, Seong Hwan; Kim, Chang Hun; Shin, Dong-Ick; Kwon, Sun U. (31 January 2023)."The Rescue on Reperfusion Damage in Cerebral Infarction by Nelonemdaz (RODIN) Trial: Protocol for a Double-Blinded Clinical Trial of Nelonemdaz in Patients with Hyperacute Ischemic Stroke and Endovascular Thrombectomy".Journal of Stroke.25 (1):160–168.doi:10.5853/jos.2022.02453.PMC 9911845.PMID 36746385.
  4. ^Hong, Ji Man; Lee, Jin Soo; Lee, Yeong-Bae; Shin, Dong Hoon; Shin, Dong-Ick; Hwang, Yang-Ha; Ahn, Seong Hwan; Kim, Jae Guk; Sohn, Sung-Il; Kwon, Sun U.; Lee, Ji Sung; Gwag, Byoung Joo; Chamorro, Ángel; Choi, Dennis W.; Chammorro, Ángel; Kim, Eung Yeop; Choi, Jin Wook; Yeo, Min-Ju; Kwak, Jaehyuk; Lee, Sung Eun; Hong, Jeong-Ho; Lee, Sangkil; Lee, Yoon-Joo; Lee, Min-Joo (November 2022)."Nelonemdaz for Patients With Acute Ischemic Stroke Undergoing Endovascular Reperfusion Therapy: A Randomized Phase II Trial".Stroke.53 (11):3250–3259.doi:10.1161/STROKEAHA.122.039649.PMC 9586831.PMID 36065810.
Stub icon

Thismedical article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Nelonemdaz&oldid=1259072310"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp